NEW YORK (GenomeWeb) – Luminex announced today it has licensed the Xtreme Chain Reaction nucleic acid amplification technology from XCR Diagnostics.

The XCR technology enables rapid thermal cycling protocols in order to reduce assay turnaround times compared to traditional PCR.

"We look forward to leveraging the benefits that the XCR technology can bring to our future molecular diagnostics portfolio," Luminex President and CEO Homi Shamir said in a statement.

Financial terms for the non-exclusive, worldwide licensing agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.